drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Biosimilar of infliximab (Remsima/CT-P13), a chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α to block TNFR1/2 signaling and downstream NF-κB activation, reducing proinflammatory cytokines, adhesion molecules, leukocyte recruitment, and keratinocyte hyperproliferation; may mediate Fc-dependent lysis/apoptosis of TNF-α–expressing cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
CT-P13
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
IgG1 monoclonal antibody biosimilar to infliximab that binds soluble and transmembrane TNF-alpha, neutralizing TNF and blocking TNFR1/2 signaling and downstream NF-kB activation; decreases proinflammatory cytokines and adhesion molecules, limits leukocyte recruitment and keratinocyte hyperproliferation; may induce Fc-mediated lysis/apoptosis of TNF-alpha-expressing cells.
drug_name
Infliximab-dyyb
nct_id_drug_ref
NCT06591273